RecruitingPhase 1NCT07300683

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

Fratricide-Resistant Autologous Chimeric Antigen Receptor T Cells Targeting CCR9 for the Treatment of T Cell Acute Lymphoblastic Leukaemia/ Lymphoma

Sponsor

University College, London

Enrollment

24 participants

Start Date

Nov 11, 2025

Study Type

INTERVENTIONAL

Conditions

T-cell Acute Lymphoblastic Leukemia T-Cell Lymphoblastic Lymphoma

Summary

The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory. * be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells. * be given the CAR T cells into their vein. * stay in the hospital for a minimum of 2 weeks to be closely monitored * following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years) * during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and/or imaging tests (CT/PET-CT scans) depending on their type of T-cell cancer.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of treatment called CAR T-cell therapy for people with T-cell leukemia or lymphoma that has come back or is not responding to treatment. CAR T-cells are immune cells that have been genetically engineered to seek out and destroy cancer cells that carry a specific protein called CCR9. **You may be eligible if...** - You have T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has relapsed or is not responding to treatment - Adults (18+) have had at least one prior treatment; younger patients need at least two prior treatments - Your cancer cells test positive for the CCR9 protein - If you have T-LBL, you have measurable disease on scans **You may NOT be eligible if...** - Your cancer cells do not express the CCR9 protein - Your overall health or performance status is too low - You have certain serious infections or other significant health problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.